PD-1/PD-L1 Immunotherapy Markets, 2030 - Clinical Importance, Commercialization Landscape, Pricing and Reimbursement Scenario, Entry of Biosimilars, Impact of COVID-19

DUBLIN, Nov. 3, 2020 /PRNewswire/ -- The "Global PD-1/PD-L1 Immunotherapy Market: Focus on Type, Application, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

Global market for PD-1/PD-L1 immunotherapy is predicted to grow at a CAGR of 10.72% over the forecast period of 2020-2030.

Cancer immunotherapy has significantly advanced in the past few years, and PD-1/PD-L1 immunotherapy has emerged out as one of the most prominent therapies. Many clinical trials have proved their significance, and many are still underway to find other cancers which can be treated with this therapy. These therapies have shown exceptional results in combination with other therapies with reasonable toxicity profile.

Further, dynamic immunologic studies, along with genetics and epigenetics in the human cancer microenvironment, are expected to guide the development of different combination therapies and generate novel insight into how the human immune system responds to and is shaped by a variety of tumor types.

The unmet medical needs in the field of treatment of cancer are significantly driving the growth of this market. Other factors driving the growth include the high prevalence of cancer and increasing expedited approvals by the FDA.

Despite the various factors that are influencing the growth of this market, there are several key issues that are needed to be addressed to facilitate future growth. The relatively high total costs of development and usage of PD-1/PD-L1 inhibitors and reimbursement policies are restraining the growth of this market.

Within the research report, the market is segmented on the basis of type, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the adoption of PD-1/PD-L1 immunotherapy at the global level has encouraged companies to invest in the development of products in the PD-1/PD-L1 immunotherapy segment for cancer treatment. Due to the diverse product portfolio and intense market penetration, Merck & Co., Inc. has been a pioneer in this field and been a significant competitor in this market.

On the basis of region, North America holds the largest share, due to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Key Topics Covered:

Executive Summary

1 Technology Definition
1.1 Inclusion and Exclusion Criteria
1.1.1 Inclusions
1.1.2 Exclusions

2 Market Scope
2.1 Key Questions Answered in the Report

3 Research Methodology
3.1 Primary Data Sources
3.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Criteria for Company Profiling

4 Market Overview
4.1 PD-1/PD-L1 Immunotherapy and Their Clinical Importance
4.2 PD-1/PD-L1 Immunotherapy Development and Commercialization Landscape
4.3 Global PD-1/PD-L1 Immunotherapy Market and Growth Potential, 2019-2030
4.4 Pricing and Reimbursement Scenario
4.5 Impact of Patent Expiry and Entry of Biosimilars on Market
4.6 Impact of COVID-19 on PD-1/PD-L1 Immunotherapy Market

5 Epidemiology of PD-1/PD-L1 Immunotherapy

6 Patent Landscape

7 Market Dynamics
7.1 Overview
7.2 Impact Analysis
7.3 Drivers
7.3.1 Rising Prevalence of Cancer
7.3.2 Unmet Medical Needs of Metastatic Cancer Patients
7.3.3 Advancements Made in the Field of Precision Medicine and Immuno-Oncology
7.3.4 Rising Awareness Among People for the Treatment of Cancer
7.3.5 Increasing Research and Development Expenditure in the Field of Oncology
7.3.6 Increase in Disposable Income
7.4 Restraints
7.4.1 Adverse Effects of PD-1/PD-L1 Immunotherapy
7.4.2 Payment Policy and Reimbursement Issue
7.4.3 High Development Cost of New Therapy
7.5 Opportunities
7.5.1 Developing Healthcare Infrastructure in Emerging Economies

8 Industry Insights
8.1 Overview
8.2 Regulatory Scenario
8.3 Legal Requirements and Frameworks in the U.S.
8.3.1 Clinical Trial Authorization
8.3.2 Marketing Authorization
8.3.3 USFDA Guidelines for BLA Submission
8.3.4 Post-Authorization Regulations
8.4 Legal Requirements and Frameworks in Europe
8.4.1 EMA Biologics License Application Process
8.4.2 Centralized Procedure
8.4.3 Decentralized Procedure
8.4.4 Mutual-Recognition Procedure
8.4.5 National Procedure
8.5 Legal Requirements and Frameworks in Asia-Pacific
8.5.1 China
8.5.2 Japan
8.6 Expedited Regulatory Designations Around the World

9 Global PD-1/PD-L1 Immunotherapy Market (by Type), $Million, 2019-2030
9.1 Introduction
9.2 PD-1 Inhibitors
9.2.1 Commercialized Therapeutics
9.2.1.1 Keytruda
9.2.1.2 Opdivo
9.2.1.3 Libtayo
9.2.2 Pipeline Therapeutics
9.3 PD-L1 Inhibitors
9.3.1 Commercialized Therapeutics
9.3.1.1 Tecentriq
9.3.1.2 Imfinzi
9.3.1.3 Bavencio
9.3.2 Pipeline Therapeutics

10 Global PD-1/PD-L1 Immunotherapy Market (by Application), $Million, 2019-2030
10.1 Introduction
10.2 Non-Small Cell Lung Cancer (NSCLC)
10.3 Hepatocellular Carcinoma (HCC)
10.4 Esophageal Cancer
10.5 Small Cell Lung Cancer (SCLC)
10.6 Urothelial Carcinoma
10.7 Others

11 Global PD-1/PD-L1 Immunotherapy Market (by Region), $Million, 2019-2030

12 Competitive Landscape
12.1 Key Developments and Strategies
12.1.1 Regulatory and Legal Developments
12.1.2 Partnerships, Alliances, and Business Expansions
12.1.3 M&A Activities
12.1.4 Funding Activities
12.2 Market Share Analysis

13 Company Profiles
13.1 Company Overview
13.2 Role of AstraZeneca Plc in the Global PD-1/PD-L1 Immunotherapy Market
13.3 Financials
13.4 Key Insights About Financial Health of the Company
13.5 SWOT Analysis

• AstraZeneca Plc
• BeiGene, Ltd.
• Bristol-Myers Squibb Company
• Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
• Eli Lilly & Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Innovent Biologics, Inc.
• Jiangsu HengRui Medicine Co., Ltd.
• Merck & Co., Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi S.A.

For more information about this report visit https://www.researchandmarkets.com/r/wove9l

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com